Growth Metrics

Takeda Pharmaceutical (TAK) Consolidated Net Income (2017 - 2025)

Historic Consolidated Net Income for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $1.1 billion.

  • Takeda Pharmaceutical's Consolidated Net Income fell 1937.44% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 billion, marking a year-over-year increase of 3346.36%. This contributed to the annual value of $709.9 million for FY2025, which is 2899.72% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Consolidated Net Income stood at $1.1 billion for Q4 2025, which was down 1937.44% from $7.5 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Consolidated Net Income peaked at $7.5 billion during Q3 2025, and registered a low of $487.8 million during Q3 2022.
  • Over the past 5 years, Takeda Pharmaceutical's median Consolidated Net Income value was $1.4 billion (recorded in 2024), while the average stood at $2.1 billion.
  • Per our database at Business Quant, Takeda Pharmaceutical's Consolidated Net Income skyrocketed by 64822.38% in 2021 and then tumbled by 7115.93% in 2022.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Consolidated Net Income stood at $761.5 million in 2021, then fell by 11.55% to $673.6 million in 2022, then surged by 161.65% to $1.8 billion in 2023, then dropped by 25.02% to $1.3 billion in 2024, then dropped by 19.37% to $1.1 billion in 2025.
  • Its Consolidated Net Income was $1.1 billion in Q4 2025, compared to $7.5 billion in Q3 2025 and $2.6 billion in Q2 2025.